Our findings identify FN1 and SPP1 as pivotal molecular targets linking endothelial dysfunction to hypertension, offering novel therapeutic insights for the prevention and treatment of cardiovascular diseases associated with nicotine exposure. Here, FN1 is linked to endothelial dysfunction.